+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effect of Central and Continuous Intravenous Injection of lnterleukin-1βon Brain c- fosExpression in the Rat: Involvement of Prostaglandins

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Utilizing immunohistochemistry for the c- fosprotein to detect neuronal activity, we examined the effects of continuous intravenous and intracerebroventricular infusion of interleukin (IL)-1βin the rat brain, and the involvement of prostaglandins (PGs) in IL-1β-induced c- fosexpression. Continuous intravenous infusion of IL-1β(10 ng/min) markedly augmented c- fosexpression in the paraventricular (PVN) and the supraoptic (SON) nuclei of the hypothalamus as well as in the central amygdaloid nucleus (CeA). The number of IL-1β-induced c- fos-positive cells in the PVN and SON was significantly lower in rats pretreated with indomethacin than in vehicle-treated rats. However, the number of IL1β-induced c- fos-positive cells in the CeA remained unchanged. c- fosprotein was induced after intracerebroventricular infusion of IL-1β(200 ng) in the PVN, SON and arcuate nuclei of the hypothalamus, and in the CeA. The induction of c- fosimmunoreactivity by central administration of IL-1βwas blocked by indomethacin (500µg/rat), except in the CeA. These findings suggest that PGs are involved in the complex transmission of signals from circulating or central IL-1βto hypothalamic neurons.

          Related collections

          Author and article information

          S. Karger AG
          08 November 1996
          : 3
          : 2-3
          : 87-92
          aDepartment of Clinical Laboratory Medicine and bFirst Department of Internal Medicine, Kagawa Medical School, Miki-Cho, Kita-Gun, Kagawa, Japan
          97232 Neuroimmunomodulation 1996;3:87–92
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article